Filtered By:
Condition: Atrial Fibrillation
Procedure: Hemodialysis
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 229 results found since Jan 2013.
The Relationship Between Atrial Fibrillation, Mitral Regurgitation, and Heart Failure Subtype: The ARIC Study
CONCLUSIONS: In patients with ADHF, AF prevalence increased with MR severity and this effect was more pronounced in HFpEF compared with HFrEF. AF was associated with an increased 1-year mortality only in patients with HFpEF and concomitant moderate/severe MR.REGISTRATION: NCT00005131, https://clinicaltrials.gov/ct2/show/NCT00005131.PMID:34955335 | DOI:10.1016/j.cardfail.2021.10.015
Source: Atherosclerosis - December 27, 2021 Category: Cardiology Authors: Sameer Arora Zachary D Brown Krishan Sivaraj Michael J Hendrickson Anthony J Mazzella Patricia P Chang Muthiah Vaduganathan Arman Qamar Anil K Gehi Ambarish Pandey John P Vavalle Source Type: research
Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry
CONCLUSION: In Japanese AMI patients, AF was often observed and was associated with worse MACE but not worse bleeding.PMID:35216889 | DOI:10.1016/j.jjcc.2022.02.007
Source: Journal of Cardiology - February 26, 2022 Category: Cardiology Authors: Hiroyoshi Mori Kazuki Fukui Atsuo Maeda Yoshihiro Akashi Junya Ako Yuji Ikari Toshiaki Ebina Kouichi Tamura Atsuo Namiki Ichiro Michishita Kazuo Kimura Hiroshi Suzuki Source Type: research
Utility of CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc Score to Predict Mid-Term Clinical Outcomes in Hemodialysis Patients
Conclusion: The CHA2DS2-VASc score is a valuable predictor of 3-year all-cause and CVD mortality in incident HD patients.Am J Nephrol
Source: American Journal of Nephrology - March 8, 2022 Category: Neurology Source Type: research
Utility of CHA2DS2-VASc Score to Predict Mid-Term Clinical Outcomes in Hemodialysis Patients
CONCLUSION: The CHA2DS2-VASc score is a valuable predictor of 3-year all-cause and CVD mortality in incident HD patients.PMID:35259747 | DOI:10.1159/000522225
Source: American Journal of Nephrology - March 8, 2022 Category: Urology & Nephrology Authors: Aiko Okubo Toshiki Doi Kenichi Morii Yoshiko Nishizawa Kazuomi Yamashita Kenichiro Shigemoto Sonoo Mizuiri Koji Usui Michiko Arita Takayuki Naito Takao Masaki Source Type: research
A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease
CONCLUSION: Further studies are still required, some ongoing, in patients with advanced CKD (CrCl < 30 ml/min) to identify the safest and most effective treatment options for VTE and AF.PMID:36006608 | DOI:10.1007/s40620-022-01413-x
Source: Journal of Nephrology - August 25, 2022 Category: Urology & Nephrology Authors: Kathrine Parker John Hartemink Ananya Saha Roshni Mitra Penny Lewis Albert Power Satarupa Choudhuri Sandip Mitra Jecko Thachil Source Type: research
Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
Front Biosci (Schol Ed). 2022 Jul 21;14(3):21. doi: 10.31083/j.fbs1403021.ABSTRACTThe most frequent arrhythmia treated is atrial fibrillation (AF), which necessitates the use of oral anticoagulants (OACs) to reduce the risk of thromboembolism and stroke. Patients with chronic kidney disease are more likely to develop AF, with a 10% frequency among those on chronic dialysis. Warfarin is the most widely prescribed OAC for individuals with end-stage kidney disease (ESKD). On the other hand, direct OACs (DOACs) are generally safer than warfarin, with fewer fatal bleeding events and a fixed dose that does not require close inte...
Source: Frontiers in Bioscience - Scholar - September 22, 2022 Category: Biomedical Science Authors: Nikolaos Ktenopoulos Marios Sagris Panagiotis Theofilis Sophia Lionaki Loukianos S Rallidis Source Type: research
